



CLL/SLL Patient Survey

Lymphoma Canada and CLL Patient Advocacy Group (CLLPAG) are preparing submissions for the panCanadian Oncology Drug Review (pCODR). You can help by completing our survey, which will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs. You do not need to live in Canada to complete this survey.

If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey - Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL; Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL/SLL; Acalabrutinib (Calquence) monotherapy for treatment of relapsed/refractory CLL/SLL.

<https://www.surveymonkey.com/r/CLLCAN2020>

Quebec first province to reimburse the combination Venetoclax + Rituximab

Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Quebec is the first province to reimburse the combination VENCLEXTA® + rituximab as a treatment for patients with Chronic Lymphocytic Leukemia (CLL). [Link to full article](#)

Changes to the CLLPAG Board of Directors

CLLPAG is pleased to announce several additions to its Board of directors. We welcome Tess Bernacki from Manitoba, Eric Pitters from Ontario, Raymond Vles from Quebec and Peter Nadler from British Columbia.

We would also like to extend our sincere thanks to Deborah Baker, cofounder of CLLPAG and longtime Chair of the Board, for her 12 years of distinguished service to CLLPAG. Deborah has resigned her position, but we are pleased and honoured to have her accept the position of Honourary Ex-Officio Member of our Board.